Armata Advances AP-SA02 Toward Phase III Bacteremia Trial
LOS ANGELES, July 20, 2026 Armata Pharmaceuticals, Inc. has announced significant clinical, regulatory, manufacturing, and operational progress supporting the...
fast track
Advertisement
Ionis Reaches Phase 3 Enrollment Milestone for Obudanersen
CARLSBAD, Calif., July 6, 2026 Ionis Pharmaceuticals announced the completion of enrollment for the pivotal pediatric cohort of its...
Cadrenal Highlights Phase 2 CAD-1005 Trial in Prestigious ISTH 2026 Session
PONTE VEDRA, Fla., June 24, 2026 Cadrenal Therapeutics, Inc. announced that late-breaking clinical data from its Phase 2 study...
CeleCor Submits FDA NDA for Zalunfiban After Phase 3 Success
DEL MAR, Calif., June 24, 2026 CeleCor Therapeutics announced the completion of its New Drug Application (NDA) submission to...
Enterome Wins FDA Orphan Tag for EO2463 in iNHL
Paris, France | May 28, 2026 Enterome announced that the U.S. FDA has granted Orphan Drug Designation (ODD) to...
Advertisements
Telix NDA Accepted for Pixclara Brain Cancer Imaging
Melbourne, Australia & Indianapolis, USA | April 10, 2026 Telix Pharmaceuticals has announced that the U.S. Food and Drug...
Advertisement
